Skip to main content

Table 1 Demographic, clinical features, immunologic data and treatment of the patients with DPPX antibodies

From: Clinical and imaging analysis to evaluate the response of patients with anti-DPPX encephalitis to immunotherapy

 

Patient 1

Patient 2

Patient 3a

Patient 4

Patient 5

Patient 6b

Patient 7

Patient 8

Patient 9

Demographic

 Sex

F

F

F

M

M

F

F

M

F

 Age at onset, y

65

47

62

35

14

51

35

54

52

 Months to onset

12

0.5

3

0.5

0.5

0.5

4

1

6

Clinical Features

 Prodromal symptoms

Headache

Fever, diarrhea

Weight loss (10 kg), diarrhea, headache;

Headache

Fever, gastroparesis and constipation

Fever, headache, weight loss (5 kg)

Vertigo, diarrhea

Headache

Fever

 Main symptoms

Memory loss, executive dysfunction, delusions, hyperreflexia

Delirium in 11 days to cognitive disorder, aphasia, limb paralysis, RBD, vertigo

Bradykinesia, tremor, memory loss, RBD, hyperreflexia, nystagmus

Stiffness, sleep disorder (insomnia), generalized seizure

Confusion, cognitive disorder, limb paralysis, respiratory failure, hyperreflexia

Memory loss, insomnia, ataxia, nystagmus

Generalized seizure, insomnia, RBD

Somnolence, cognitive disorder, myoclonus, insomnia

Delirium, cognitive disorder, recurrent generalized seizures,

 Brain MRI

Bilateral hippocampus T2/FLAIR increased signals

Bilateral temporal lobe and amygdala T2/FLAIR increased signals

Nonspecific white matter changes

Left hippocampus and basal ganglia T2/FLAIR increased signals

Extensive abnormal signals in the brainstem, basal ganglia and bilateral white matter

Extensive abnormal signals in the frontal lobe, basal ganglia, hippocampus and cerebellum

Normal

Nonspecific white matter changes

Bilateral temporal lobe, hippocampus and left frontal lobe T2/FLAIR increased signals

Immunologic data

 CSF

WBC: normal Protein: normal

WBC: normal Protein: normal

WBC: normal Protein: normal

December 2018 WBC: 370, Protein: 852 January 2019 WBC: 20, Protein 549

March 2019 WBC: 220, Protein:2096 May 2019 WBC: 10, Protein: 469

WBC: normal Protein: normal

WBC: normal Protein: normal

WBC: normal Protein: 958

November 2018 WBC (−), Protein: 609 December 2018 WBC (−), Protein (−)

 DPPX antibody

Serum: 1:100 CSF: ND

Serum: 1:10 CSF: ND

Serum: 1:32 CSF: ND

Serum: 1:32 CSF: 1: 3.2

Serum: 1:320 CSF (−)

Serum: 1:100 CSF: 1:1

Serum: 1:10 CSF: (−)

Serum: 1:1000 CSF: 1:10

December 2018 Serum:1:10 CSF: (−) October 2019 Serum:1:32 CSF: ND

 Treatment/response

IVMP, oral steroids/ marked improvement

IVMP, oral steroids/ marked improvement, but relapsed with steroid taper

Oral steroids/ marked improvement

IVMP, Tacrolimus/ mild, but steady improvement

IVMP, IVIg/ incomplete improvement

IVMP, Rituximab/ marked improvement

IVMP, oral steroids/ marked improvement

IVMP, oral steroids/ marked improvement

IVMP, oral steroids/ marked improvement, but relapsed with steroid taper

  1. Abbreviations: DPPX dipeptidyl-peptidase-like protein-6, ND not done, IVMP intravenous methylprednisolone, IVIg intravenous immunoglobulins
  2. a Micropapillary carcinoma of thyroid was found during the course of the disease
  3. b Non-Hodgkin’s lymphoma was found during the examinations